Combipatch Transdermal Patch Recall Due to Stability Failure
Noven Pharmaceuticals is recalling certain lots of Combipatch (estradiol/norethindrone acetate transdermal system) distributed nationwide because the patches failed stability testing and fell out of specification for shear properties.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall for a stability and manufacturing-specification failure. No illnesses, injuries, or deaths are reported in the source text. The hazard is potential reduced efficacy or delivery inconsistency due to out-of-specification shear properties, which is a quality and performance issue rather than an acute safety threat.
Plain-English summary
Noven Pharmaceuticals Inc is recalling Combipatch (estradiol/norethindrone acetate transdermal system) 0.05/0.25 mg per day in packages of 2 systems (NDC 68968-0525-2) and 8 systems (NDC 68968-0525-8). The recall affects lots 88540 (expiration 03/2022), 89118 (expiration 05/2022), 89244 (expiration 07/2022), and a sample lot 89244 (expiration 07/2022). The product was distributed nationwide.
The patches are being recalled because they failed stability specifications and were found to be out of specification for shear properties. Shear refers to the physical integrity and adhesive properties of the transdermal patch.
Patients who have this product should consult their healthcare provider about continued treatment options. Healthcare providers and patients who have questions about this recall can contact Noven Therapeutics LLC or the FDA for more information.
The recalled product
- Product
- COMBIPATCH (ESTRADIOL/NORETHINDRONE ACETATE TRANSDERMAL SYSTEM) (ESTRADIOL/NORETHINDRONE ACETATE TRANSDERMAL SYSTEM)
- Brand
- COMBIPATCH (ESTRADIOL/NORETHINDRONE ACETATE TRANSDERMAL SYSTEM)
- Manufacturer
- Noven Pharmaceuticals Inc
- Affected units
- 70,638
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lots: 88540 Exp. 03/2022
- 89118 Exp. 05/2022
- 89244 Exp. 07/2022
- 89244 (sample lot) Exp. 07/2022
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Noven Pharmaceuticals Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · COMBIPATCH (ESTRADIOL/NORETHINDRONE ACETATE TRANSDERMAL SYSTEM)
- ModerateCombipatch Transdermal System Recalled for Failed Stability Specifications
FDA (Drugs) · 2021-08-25
Same manufacturer · Noven Pharmaceuticals Inc
See all →- HighPrescription Dextroamphetamine Patches Recalled for Defective Adhesive System
FDA (Drugs) · 2024-11-27
- HighDaytrana Methylphenidate Patches Recalled for Defective Transdermal Delivery System
FDA (Drugs) · 2023-03-29
- ModerateDaytrana Methylphenidate Patches Recalled for Defective Delivery System
FDA (Drugs) · 2023-03-29
- HighDaytrana methylphenidate patches recalled for defective delivery system
FDA (Drugs) · 2023-03-29
- HighDaytrana Methylphenidate Transdermal Patches Recalled for Defective Delivery System
FDA (Drugs) · 2023-03-29
Same hazard · stability failure
See all →- LowChiesi Recalls Revcovi Injection Due to Stability Specification Failure
FDA (Drugs) · 2026-09-09
- ModerateMylan Recalls Prasugrel Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-09
- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateZone 2 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 1 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11